Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by jts115on Feb 08, 2013 3:54pm
152 Views
Post# 20960985

RE: so how are my numbers

RE: so how are my numbers

Your numbers are sketchy at best. To derive a valuation you have to compare the company to its peers. All its peers are larger, better capitalized and in a later stage of development of their blocks. The company is difficult to value as a whole but you can value it in parts. It is strange to value a company on the basis of revenue (90$ a barrel*400 Barrels a day) rather than on profit potential. The best way to calculate the liquidation value of the company's productive properties is to either use your flowing barrel model and compare it to a peer group:

lets say the company is producing 500 net bopd and multiply that by 30,000 to 50,000 per flowing barrel (similar to peer group) and you come upon a rough valuation of 15-25 Million Dollars.


The other method you could use is taking p1 reserves of 10Million and 50% of probable reserves (to reflect the probability of their production) and the reserve value comes down to 15 Million dollars PV10.

I would say that these two estimates are innacurate but I would assess value in the following way:

Giving whole value to P2 PV10 ~30 Million

Applying 2M dollars in value to the 10% interest in guatemala

Adding 8 Million in GICs and drilling committments that will eventually amount ot wells

Compiling this valuation I come upon a somewhat presumptious 40 Million dollar valuation which amounts to 60 cents a share or so. I believe this is what the company is worth up for sale. In bankruptcy it is probably worth 15-20 Million dollars.

Bullboard Posts